Clinical Trials Browser

Mesothelioma, Malignant, COVID-19, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Melanoma, Myelodysplastic Syndromes, Pancreatic Neoplasms, Leukemia, Myeloid, Acute

NCT02488408 2024-12-19

A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS

Phase 1/2 Completed

122 enrolled 29 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02922777 2024-02-21

Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.

Phase 1 Completed

23 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03965494 2024-02-08

AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery

Phase EARLY_PHASE1 Terminated

10 enrolled

CNS

Glioblastoma, Central Nervous System Neoplasms

NCT03649321 2023-11-09

Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer

Phase 1/2 Terminated

9 enrolled 12 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03654833 2023-03-14

MiST

Phase 2 Unknown

186 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT03824080 2021-12-21

Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes

Phase 2 Completed

45 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03184558 2021-11-09

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

Phase 2 Terminated

29 enrolled 10 charts

Breast

Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms